Alcidion Group Limited · ASX:ALC
Alcidion — Investor Presentation (August 2023)
31 slides from Alcidion's investor presentation, Aug 24, 2023
Slide 1: FY23 Results Investor Presentation
FY23 Results Investor Presentation 24 AUGUST 2023
Slide 2: Making the right thing to do, the easiest thing to do
Alcidion helps healthcare organisations harness the power of technology to create a clinically relevant environment with digitally enabled care… “Making the right thing to do, the easiest thing to do” 2
Slide 3: Alcidion – a snapshot
Alcidion – a snapshot • Healthcare software and informatics company providing an innovative technology platform to improve the efficiency and quality of patient care • Aggregate and analyse data, using AI to enable a proactive (rather than reactive) approach to patient care • 400+ hospitals across 9
Slide 4: Challenges We Seek to Address
Challenges We Seek to Address Designed for Modern Healthcare Patient Safety • Highly interoperable & built on open standards • Designed to be an active participant in health Clinical Productivity care rather than passive data store • Applies Clinical Decision Support(CDS), AI, Patient Flow & Logisti
Slide 5: Miya Precision
5 Miya Precision Miya Precision - an Tailored clinical decision Responsive to new clinical innovative platform, information support engineering risk consolidating data in open out of healthcare FHIR standards Uses open standards & Creates ecosystem for integrates with any solution innovation & p
Slide 6: FY23 Highlights
FY23 Highlights
Slide 7: FY23 – Financial Highlights
FY23 – Financial Highlights Continuing to build scale through increased recurring revenue supported by positive operating cashflow Revenue $40.4M 18%1 Recurring Revenue $28.1M 21% Gross Margin 86.1% 0.3pts Sold Revenue For FY242 $33.7M 8% EBITDA ($1.5M) $0.1M FY23 TCV3 new sales $29.9M 48% Operating
Slide 8: FY23 – Operational Highlights
FY23 – Operational Highlights • $29.9m of new and renewal contracts signed in FY23 Overview • In UK market, Alcidion has at least one Miya Precision module in 38 NHS Trusts (~28%) of all acute NHS sites) • University Hospitals Southampton (UHS) NHS Trust (UK): Initial 3-year contract to implement Mi
Slide 9: Strategy and Outlook
Strategy and Outlook Modular sales approach • Modular approach to implementing Miya Precision platform continuing to resonate with customers – Highlighted by additional UK module wins with Dartford & Gravesham, Derby and Bolton – Foothold with at least one module in 28% UK Trusts provides a streamli
Slide 10: FY23 Financials
FY23 Financials
Slide 11: Profit & Loss
Profit & Loss Key Comments Profit & loss ($000) FY23 FY22 % change Recurring revenue 28,143 23,274 21% • FY23 revenue of $40.4M, up 18% on FY22 Non-recurring revenue 12,257 11,081 11% Total revenue 40,400 34,355 18% A$M Products Product Imp Services Total Direct costs (5,629) (4,862) 16% Recurring 2
Slide 12: Revenue Dashboard
Revenue Dashboard Half-on- half revenue Geographical Split (FY23) (UK / ANZ) UK ANZ Recurring / non- recurring revenue 12
Slide 13: Our revenue model and breakdown…
Our revenue model and breakdown… Licence fees + Maintenance & Support (M&S) recurring revenue underpin sustainable and increasingly profitable growth Core Offering Products ~94%1 Technical Services ~6%1 Key Product / Data analytics, Integration, Services interoperability & technical design Revenue S
Slide 14: Balance Sheet
Balance Sheet Balance sheet ($000) FY23 FY22 Cash & cash equivalents 14,641 17,339 Key Comments Trade & other receivables 4,735 7,251 Other assets 1,602 1,672 • Strong balance sheet with $14.6M cash and no debt Current assets 20,978 26,262 Plant & equipment 729 638 – Reduction in cash primarily driv
Slide 15: Cash Flow
Cash Flow Cash flow ($000) FY23 FY22 Key Comments Receipts from customers 46,901 41,449 Payments to suppliers & employees (46,728) (40,275) • Record $46.9M receipts from customers, up 13% on FY22 Interest received 111 24 Finance costs (115) (68) • Positive operating cashflow of $0.2M Income tax paid
Slide 16: FY23 Operations
FY23 Operations
Slide 17: Notable Contract Wins and Renewals
Notable Contract Wins and Renewals New contracts reinforce modular strategy, catering to needs of customers as they enhance their digital maturity • University Hospital Southampton • Royal Wolverhampton NHS Trust (UK): (UK): 4 Miya Precision modules with 2-year contract renewal agreement for use opt
Slide 18: Successful Deployments
Successful Deployments Product Implementation and technical services have always been a strength of the Alcidion business • Alfred Hospital: Successful go live across • Leidos Australia (ADF): Continued three campuses early 2023 using Miya successful, staged delivery of the project to Precision, dep
Slide 19: Case Study: Smartpage, helping reduce medical errors
Case Study: Smartpage, helping reduce medical errors Smartpage is an advanced smartphone and web-based system for hospital communication and task management, addressing the requirements of both clinical and non-clinical users. 2022 junior doctor survey at Lancashire Teaching Hospital NHS (UK): Encry
Slide 20: Miya Precision – leveraging AI and NLP
Miya Precision – leveraging AI and NLP1 • Using AI and deeply embedded NLP Miya Precision enables clinical risk detection • Flexible Clinical Decision Support (CDS) such as… – Use CDS to monitor patients in the home for deterioration (remote or virtual care) – Identify critical results and notify ca
Slide 21: ESG Highlights
ESG Highlights Employee Engagement & Wellbeing Supporting Families Diversity & Inclusion • Employee Assistance Program, monthly • Implemented new Paid Parental and • >50% female representation across senior wellbeing themes, mental health first Miscarriage Leave policy with industry executive leader
Slide 22: Market Position & Opportunity
Market Position & Opportunity
Slide 23: Our Solution…Miya Precision platform
Our Solution…Miya Precision platform Alcidion has built a smart platform for healthcare - Miya Precision, a cloud-native, modern, modular, open architecture platform taking on the major global incumbents Modern | Modular | Cloud native | Device agnostic | Clinician centric | Open Standards Patient S
Slide 24: Our sales strategy: Modular sales driving TCV uplift
Our sales strategy: Modular sales driving TCV uplift Miya Precision’s modular design supports a ‘land & expand’ strategy to support automation and digitalization in healthcare *For illustrative purposes only Ability over time to replicate full EPR contract value (US$15m - $30m) via modular add-ons $
Slide 25: Significant Growth Opportunity in UK…
Significant Growth Opportunity in UK… Government Bodies NHS England + NHSX Alcidion’s Customer (Future, ICS* ICS #1 ICS #2 (42) albeit still emerging) Trusts Alcidion’s Customer (Today) T #1 T #2 T #3 T #4 T #5 T #6 (~146 Acute) • ~38 (27%) NHS Trusts with at least one Alcidion product Hospitals H1
Slide 26: Global expansion potential…
Global expansion potential… Current Operations Future Geographical Expansion Key Criteria: Australia & New United • Sizable market Zealand Kingdom • English speaking (reduced development spend) • Healthcare structure similar to UK / Australia • Access to digital healthcare data 51% FY23 Revenue Targ
Slide 27: Outlook
Outlook
Slide 28: Looking forward…accelerating our momentum
Looking forward…accelerating our momentum Key Comments • $33.7M of contracted and scheduled renewal revenue for FY24 (as of 30 June 2023, before any new sales) • Strong balance sheet with cash of $14.6m and no debt (as of 30 June 2023) • Deep engagement with new and existing customers relating to fu
Slide 29: Investment Highlights
Investment Highlights • Large Addressable Market Strong Financial Profile Marquee Customers • 146 Acute UK NHS Trusts; ALC with foothold • ~70% recurring revenue, supported by • $31.7M over 5.5 years with Leidos (Aus) to in only approximately 27% multi-year contracts assist Australian Defence Force
Slide 30: Disclaimer
Disclaimer The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as “Alcidion” or “Company”). This Document is current as at the date of this Document and should be read in conjunction with other Alcidion periodic and continu
Slide 31: Slide 31